A randomized controlled patient blinded trial of Actiq in combination with midazolam as premedication for bone marrow biopsy in patients with hematologic malignancies

Trial Profile

A randomized controlled patient blinded trial of Actiq in combination with midazolam as premedication for bone marrow biopsy in patients with hematologic malignancies

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Jul 2017

At a glance

  • Drugs Fentanyl (Primary) ; Midazolam (Primary) ; Lidocaine
  • Indications Pain
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 Jul 2017 New trial record
    • 25 Jun 2017 Results presented at the 22nd Congress of the European Haematology Association
    • 25 Jun 2017 Primary endpoint (Efficacy) has been met, according to the abstract presented at the 22nd Congress of the European Haematology Association..
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top